MARLBOROUGH, Mass.,
Sept. 15, 2017 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs, announced today the
departure of Dr. Alexey Eliseev,
Chief Business Officer of the Company, effective immediately. Dr.
Eliseev, former CEO of MirImmune Inc., joined RXi on January 6, 2017 as Chief Business Officer of RXi
Pharmaceuticals in connection with the Company's acquisition of
MirImmune. MirImmune was a privately-held company developing
cell-based therapeutics for cancer treatments based on a license to
RXi's proprietary self-delivering RNAi technology. In his role as
Chief Business Officer of RXi, Dr. Eliseev was responsible for the
integration of this new therapeutic approach into the activities of
RXi Pharmaceuticals, and for introducing the Company to several key
industry and academic groups active in this emerging field.
Logo
- http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Geert Cauwenbergh, President
and CEO of RXi Pharmaceuticals stated that, "The Company would like
to thank Dr. Eliseev for his support in integrating MirImmune into
our Company's day-to-day activities, and for providing RXi exposure
to some of the key players in this new and exciting space." He
added that, "We wish Dr. Eliseev well in his new entrepreneurial
initiatives."
The Company also announced that Dr. James Cardia, RXi's current Director of Business
Development and Intellectual Property will take over the management
of the various ongoing activities in partnering and business
development. During his tenure at RXi, Dr. Cardia's group was
responsible for the discovery and optimization of "self-delivering"
rxRNAs (sd-rxRNAs®) as well as the development and characterization
of RXI-109, a promising anti-fibrotic agent currently in clinical
trials for the treatment of both dermal and retinal
scarring. He has participated in multiple out-licensing,
in-licensing and acquisition deals and has contributed to
numerous publications and patent applications. Dr. Cardia has
a Ph.D. in chemistry from Boston
College and received postdoctoral training in the Department
of Chemistry and Chemical Biology at Harvard
University.
On August 10, 2017, the Company
reported its financial results for the second quarter
ended June 30, 2017, and provided a business update. As
noted in that press release and related transcript, the Company
remains on track with its expected read-outs for several of its
ongoing programs in immuno-oncology, dermatology and
ophthalmology.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which can be used to "silence" or
down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform, including self-delivering RNA
(sd-rxRNA®) compounds, that have the ability to highly selectively
block the expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology, and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas, and we actively pursue
research collaborations, partnering and out-licensing opportunities
with academia and pharmaceutical companies. For additional
information, visit the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
View original
content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-the-departure-of-dr-alexey-eliseev-as-chief-business-officer-300520630.html
SOURCE RXi Pharmaceuticals Corporation